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Abstract
The etiology of anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitides (AAV) is unknown, but the association
between infections and autoimmunity has been studied extensively. In 2004, a novel theory was proposed that could link
infection and autoimmunity. This ‘theory of autoantigen complementarity’ was based on the serendipitous finding of
antibodies against complementary-PR3 (cPR3) in patients with PR3-ANCA-associated vasculitis. cPR3 demonstrated
homology to several bacterial proteins, and it was hypothesized that PR3-ANCA develop in response to anti-cPR3
antibodies, as a consequence of the anti-idiotypic network. These data have not been confirmed in other patient cohorts.
We investigated the presence of anti-cPR3 antibodies in a Dutch cohort of PR3-ANCA-associated vasculitis patients. Anti-
cPR3 reactivity was determined in serum using ELISA. Two separate batches of cPR3 were used to determine reactivity in
two separate cohorts of PR3-ANCA-associated vasculitis patients. We found that anti-cPR3-reactivity was not increased in
our PR3-ANCA-associated vasculitis patients, in comparison to control groups. Further research will be necessary to prove
the concept of autoantigen complementarity in autoimmune diseases.
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Introduction
Anti-neutrophil cytoplasmic antibodies (ANCA) associated
vasculitides (AAV) affect small- to medium-sized blood vessels,
leading to damage to upper and lower airways, kidneys and other
organs. In Wegener’s granulomatosis (WG), a prototype AAV,
ANCA are mainly directed against proteinase 3 (PR3) [1,2].
The etiology of WG is unknown, but it has been hypothesized
that WG could be triggered by a bacterial or viral infection. Sixty-
three percent of patients with WG are chronic nasal carriers of
Staphylococcus aureus and carriage is associated with an increased risk
forrelapses[3–7].Thedevelopmentofcross-reactiveantibodies asa
result of molecular mimicry has been suggested as a mechanism to
connect infections and autoimmunity [4,8–10], and recent studies
suggest a role for molecular mimicry in ANCA-associated vasculitis.
In patients with focal necrotizing glomerulonephritis, Kain et al.
found autoantibodies against lysosome-associated membrane pro-
tein-2 (LAMP-2), which cross-reacted with bacterial FimH,
suggesting that anti-LAMP-2 antibodies could be the consequence
of a cross-reactive anti-FimH response [11]. Another theory was
proposed by Pendergraft et al. after they accidentally found anti-
idiotypic antibodies in patients with PR3-ANCA-associated vascu-
litis [12]. Anti-idiotypic antibodies are developed against variable
regions of other antibodies and are suggested to play a role in
immune regulation and immunological memory [13–15]. In 7 out
of 34 patients with PR3-ANCA-associated vasculitis, Pendergraft
et al. found antibodies binding to a protein complementary to the
middle part of PR3, and therefore named cPR3m [12]. cPR3m-
immunized mice developed both anti-cPR3m antibodies and PR3-
ANCA, demonstrating that cPR3m could induce the formation of
PR3-ANCA in vivo. They hypothesized that a mimic of cPR3m
could induce the production of anti-cPR3m antibodies, and
subsequently PR3-ANCA via the anti-idiotypic network. Potential
cPR3m-homologous structures were found in various pathogens,
and it was proposed that a cPR3m-homologous microbial protein
could initiate the autoimmune response against PR3 [12].
Although these studies presented promising data that could
mechanistically connect infections and PR3-ANCA-associated
vasculitis, these findings await confirmation from other patient
cohorts. Here we present data on antibody reactivity against
cPR3m in patients with ANCA-associated vasculitis.
Materials and Methods
Patients
Anti-cPR3m reactivity was determined in two separate cohorts of
patients with PR3-ANCA associated vasculitis. In-house produced
cPR3m was used to test anti-cPR3m reactivity in serum from 57
ANCA-associated vasculitis patients, and 24 age-and-sex-matched
healthy individuals. The study was approved by the Medical Ethics
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consent was given by the participants for their serum samples to
be stored and to be used for research. Patient characteristics are
shown in table 1. Diagnoses were based on the Chapel Hill
Consensus Conference definitions. A second selection of PR3-
ANCA-associated vasculitis patients was tested for anti-cPR3m
reactivity, using cPR3m kindly provided by Dr. G. Preston
(Chapel Hill, USA). Sera from 37 consecutive PR3-ANCA-
positive Wegener’s granulomatosis patients (median ANCA titer
1:160, range 1:20-1:640) were analyzed in this assay. cPR3m-
reactivity in these patients was compared to that in 21 age-and
sex-matched healthy controls.
Recombinant cPR3m
cPR3m was produced using cPR3m plasmid DNA, kindly
provided by Dr. Preston [12]. Purified cPR3m was visualized by
Coomassie blue staining after SDS-PAGE. In addition to in-house
produced cPR3m, we used cPR3m that was kindly provided by
Dr. Preston [12].
Table 1. Patient characteristics.
ANCA specificity PR3-ANCA MPO-ANCA
Total number (diagnosis/follow-up) 34 (25/9) 23 (18/5)
Men/women 19/15 11/12
Age (mean 6 sd) 59615 62612
Diagnosis
Wegener’s granulomatosis 31 4
Microscopic polyangiitis 3 14
Necrotizing Crescentic Glomerulonephritis 5
BVAS (median/range)
diagnosis samples 21 (6–33) 17 (9–29)
ANCA: Anti-neutrophil cytoplasmic antibodies.
PR3: Proteinase 3.
MPO: Myeloperoxidase.
BVAS: Birmingham Vasculitis Activity Score.
doi:10.1371/journal.pone.0017972.t001
Figure 1. Characterization of in-house produced cPR3m. cPR3m was produced using cPR3 plasmid-DNA provided by Dr. Preston. The protein was
purified and visualized by coomassie blue staining after SDS-PAGE. The approximate molecular weight of the protein was 13 kDa. Both Rabbit-a-cPR3 (B) and
Chicken-a-cPR3 (C) antibodies bound in a concentration dependant manner to cPR3m in ELISA. D) Binding of mouse-a-HIStag antibody to cPR3m in ELISA.
doi:10.1371/journal.pone.0017972.g001
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cPR3m ELISAs were performed according to the protocol as
described by Pendergraft et al. with minor modifications [12].
Briefly, Corning Costar 9018 High Binding ELISA plates were
coated with cPR3m (5 mg/ml) in carbonate buffer. Plates were
washed with PBS/0.05% Tween-20 and blocked for 1 hour with
PBS/1% BSA/0.05% Tween-20 (incubation buffer). Plates were
washed and serum samples (diluted 1:100 in incubation buffer)
were incubated 2 h at room temperature. Binding of anti-cPR3m
antibodies was detected by alkaline phosphatase labeled anti-
human IgG (Sigma). Optical density was measured 60 minutes
after adding p-nitrophenyl phosphate substrate at 405 nm.
Antibodies
Rabbit-anti-cPR3 and chicken-anti-cPR3 antibodies were
kindly provided by Dr. Preston, and used as positive controls in
cPR3m-ELISAs. Monoclonal anti-HIStag-antibody was obtained
from Qiagen.
Nasal carriage of Staphylococcus aureus
ANCA-associated vasculitis patients who visit our outpatient
clinic are routinely tested for nasal carriage of S. aureus as described
before [6].
Statistics
Statistical analyses were performed using Graphpad Prism 5.0.
The nonparametric Mann-Whitney U test was used to compare
anti-cPR3m reactivity between groups. P values lower than 0.05
(2-tailed) were considered significant.
Results
Characterization of cPR3m
Purified cPR3m was visualized by Coomassie blue staining after
SDS-PAGE, and detected at a molecular weight of approximately
13 kDa (figure 1A). A rabbit-a-cPR3m (figure 1B), a chicken-a-
cPR3m, and a mouse a-HIS-tag antibody (figure 1C, 1D) were
found to specifically bind purified cPR3m protein in ELISA,
indicating proper production and purification of the protein.
Anti-cPR3m reactivity in AAV patients
Anti-cPR3m reactivityinAAV patient serumsamplesand healthy
controls (HC) was determined by ELISA, using in-house produced
cPR3m. Anti-cPR3m reactivity was significantly decreased in PR3-
ANCA positive patients, compared to both HC (figure 2A, P=0.04)
and MPO-ANCA positive patients (figure 2A, P=0.01). Anti-
cPR3m reactivity did not differ between patients at diagnosis (closed
circles) or during follow-up (open circles) of the disease.
In addition to in-house produced cPR3m, we used cPR3m
provided by Dr. Preston to determine anti-cPR3m reactivity in a
cohort of 37 consecutive PR3-ANCA positive WG patients. In line
with previous results, anti-cPR3m antibody reactivity in patients
was significantly lower than reactivity in HC (figure 2B, P=0.004).
Anti-cPR3m reactivity did not differ between active patients
(closed circles) and patients in remission (open circles).
To study possible idiotypic interactions between anti-cPR3m
antibodies and PR3-ANCA, we studied whether sera with high
PR3-ANCA titers could inhibit anti-cPR3 reactivity in high-cPR3
reactive sera. However, pre-incubation with neither single PR3-
ANCA sera, nor isolated PR3-ANCA IgG samples reduced
cPR3m-reactivity in high-cPR3m reactive sera, indicating that
PR3-ANCA did not bind anti-cPR3m antibodies in these assays
(data not shown).
We investigated a possible relation between nasal carriage of S.
aureus and the presence of anti-cPR3m antibodies. Anti-cPR3
reactivity in sera from nasal S. aureus carriers (median OD 0.37,
range 0.12–2.76) did not differ significantly from reactivity in non-
carriers (median OD 0.30, range 0.16–1.17).
Discussion
In 2004, the ‘theory of autoantigen complementarity’ was
presented, proposing that anti-idiotypic antibodies could play a
role in the development of autoimmune diseases. The theory was
based on the observation of anti-cPR3m antibodies in patients
Figure 2. Anti-cPR3m reactivity in serum of AAV patients and
healthy controls. A) Anti-cPR3 reactivity in ANCA-associated vasculitis
patients and controls, determined by ELISA using in-house produced
cPR3m. Anti-cPR3m-reactivity in PR3-ANCA positive patient sera was
significantly lower than reactivity in healthy controls (HC) (P=0.04) and
MPO-ANCA patients (P=0.01). Anti-cPR3m reactivity in MPO-ANCA
positive patients and HC was comparable. In neither PR3-ANCA nor
MPO-ANCA positive patients, significant differences were found
between samples at the time of disease diagnosis (closed circles) or
during follow-up (open circles). B) Anti-cPR3 reactivity in PR3-ANCA
positive Wegener’s granulomatosis patients and HC, determined by
ELISA using cPR3 provided by Dr. Preston. Anti-cPR3m reactivity was
decreased in patients, compared to HC (P=0.004). Reactivity in patients
at the time of diagnosis (closed circles) did not differ from reactivity in
patients in remission.
doi:10.1371/journal.pone.0017972.g002
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finding has not been confirmed by others. The aim of our study
was to investigate the presence of anti-cPR3m antibodies in a
different cohort of patients with ANCA-associated vasculitis, in
order to confirm data on this new type of antibody.
We successfully produced cPR3m protein in our laboratory.
Quality of the cPR3m was tested by ELISA using heterologous
anti-cPR3m antibodies. Both rabbit-anti-cPR3m and chicken-
anti-cPR3m antibodies reacted strongly with our cPR3m prepa-
ration in ELISA.
Having produced and validated cPR3m, reactivity against
cPR3m was determined in ANCA-associated vasculitis patients.
Anti-cPR3m reactivity was significantly decreased in PR3-ANCA
associated vasculitis patients, in comparison to both healthy controls
(HC) and MPO-ANCA associated vasculitis patients. The assump-
tion that cPR3m mimics a bacterial protein may explain anti-
cPR3m reactivity in control groups. Since the immune system is
continuously challenged by pathogens, antibodies against a cPR3m-
mimic may have been developed. However, Pendergraft et al. found
anti-cPR3m reactivity in neither healthy controls nor MPO-ANCA
positive patients, supporting the hypothesis that anti-cPR3m
antibodies are specifically present in patients with circulating
PR3-ANCA [12,16]. The ‘theory of autoantigen complementarity’
hypothesized that anti-cPR3m antibodies may initiate disease in
PR3-ANCA associated vasculitis. Therefore, higher anti-cPR3m
levels may be present during the early phase of disease. However,
wefoundcomparableanti-cPR3mreactivityinserumsamplestaken
at disease diagnosis and during disease follow-up.
Although the in-house produced cPR3m demonstrated good
reactivity with anti-cPR3 antibodies in ELISA, we performed an
additional assay, using cPR3m provided by Dr. Preston, to
determine anti-cPR3m reactivity in our patient cohort. In this
assay we analyzed 37 consecutive Wegener’s granulomatosis
patients with a positive PR3-ANCA titer. In line with our former
finding, this separate group of PR3-ANCA positive vasculitis
patients had significantly lower anti-cPR3m reactivity than HC.
The fact that we observed decreased anti-cPR3m reactivity in
two separate groups of PR3-ANCA positive patients is intriguing
and in contrast with the observations by Pendergraft et al. who
demonstrated anti-cPR3m antibodies in 7 out of 34 patients with
PR3-ANCA associated vasculitis. In the same study they showed
that anti-cPR3m and anti-PR3 antibodies form an idiotypic pair
[12]. Circulating anti-idiotypic antibodies have been observed in
AAV patients and it has been shown that antibody reactivity may
be masked by idiotypic antibodies [18–21]. Therefore, formation
of PR3-ANCA – anti-cPR3 complexes may have masked anti-
cPR3m reactivity in our assays. On the other hand, Pendergraft et
al. selected PR3-ANCA positive patients as well, and did find anti-
cPR3 antibodies, although PR3-ANCA titers in these patients
were not described. We studied possible idiotypic complex
formation in vitro, but were not able to demonstrate this.
Proteins from several pathogens were suggested to mimic
cPR3m, amongst which two proteins from Staphylococcus aureus
[12]. Development of antibodies against proteins from S. aureus,i n
particular by nasal carriers, has been shown [22,23]. Therefore,
we investigated a possible relationship between nasal carriage of S.
aureus and anti-cPR3m reactivity in AAV patients. Reactivity
against cPR3m did not differ significantly between nasal carriers
and non-carriers of the bacterium.
In summary, we conclude that, analyzed by the methods as
described here, reactivity against cPR3m was not increased in our
PR3-ANCA-associated vasculitis patients. In fact, we found
significantly decreased anti-cPR3m reactivity in PR3-ANCA-
associated vasculitis patients, compared to both HC and MPO-
ANCA patients. This intriguing result may be explained by the
hallmark characteristic of anti-idiotypic antibodies that they
recognize each other, thereby masking anti-cPR3 reactivity, but
we were not able to prove this. Further research is necessary to
increase the understanding on anti-cPR3 antibodies in patients
with PR3-ANCA associated vasculitis and to conclude about the
possible role of anti-idiotypic antibodies in the development of
ANCA-associated vasculitis.
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